313 related articles for article (PubMed ID: 35453784)
1. Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Park H; Park H; Baek J; Moon H; Ro SW
Biology (Basel); 2022 Apr; 11(4):. PubMed ID: 35453784
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.
Li Q; Sun M; Wang M; Feng M; Yang F; Li L; Zhao J; Chang C; Dong H; Xie T; Chen J
Cancer Sci; 2021 May; 112(5):1695-1706. PubMed ID: 33605517
[TBL] [Abstract][Full Text] [Related]
3. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of WNT/β-catenin signaling for hepatocellular carcinoma.
Asaoka Y; Tanaka A
Glob Health Med; 2020 Oct; 2(5):269-272. PubMed ID: 33330820
[TBL] [Abstract][Full Text] [Related]
6. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
[TBL] [Abstract][Full Text] [Related]
7. Protein tyrosine phosphatase receptor type D (PTPRD)-mediated signaling pathways for the potential treatment of hepatocellular carcinoma: a narrative review.
Huang X; Qin F; Meng Q; Dong M
Ann Transl Med; 2020 Sep; 8(18):1192. PubMed ID: 33241041
[TBL] [Abstract][Full Text] [Related]
8. 4-Acetylantrocamol LT3, a New Ubiquinone from
Chen YL; Yen IC; Lin KT; Lai FY; Lee SY
Am J Chin Med; 2020; 48(5):1243-1261. PubMed ID: 32668963
[TBL] [Abstract][Full Text] [Related]
9. Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma.
Morita M; Nishida N; Aoki T; Chishina H; Takita M; Ida H; Hagiwara S; Minami Y; Ueshima K; Kudo M
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190239
[TBL] [Abstract][Full Text] [Related]
10. Interacting network of Hippo, Wnt/β-catenin and Notch signaling represses liver tumor formation.
Kim W; Khan SK; Yang Y
BMB Rep; 2017 Jan; 50(1):1-2. PubMed ID: 27881216
[TBL] [Abstract][Full Text] [Related]
11. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
[TBL] [Abstract][Full Text] [Related]
12. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma.
Dimri M; Satyanarayana A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32093152
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicle-Based Therapeutic Targeting of β-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer.
Matsuda A; Ishiguro K; Yan IK; Patel T
Hepatol Commun; 2019 Apr; 3(4):525-541. PubMed ID: 30976743
[TBL] [Abstract][Full Text] [Related]
14. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
15. Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.
Morita M; Nishida N; Sakai K; Aoki T; Chishina H; Takita M; Ida H; Hagiwara S; Minami Y; Ueshima K; Nishio K; Kobayashi Y; Kakimi K; Kudo M
Liver Cancer; 2021 Jul; 10(4):380-393. PubMed ID: 34414125
[TBL] [Abstract][Full Text] [Related]
16. Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis.
Kim W; Khan SK; Gvozdenovic-Jeremic J; Kim Y; Dahlman J; Kim H; Park O; Ishitani T; Jho EH; Gao B; Yang Y
J Clin Invest; 2017 Jan; 127(1):137-152. PubMed ID: 27869648
[TBL] [Abstract][Full Text] [Related]
17. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
[TBL] [Abstract][Full Text] [Related]
18. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
19. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
Front Oncol; 2018; 8():269. PubMed ID: 30057891
[TBL] [Abstract][Full Text] [Related]
20. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
